For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
